Sveits - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - riociguatum - compresse rivestite con film - riociguatum 1.5 mg, cellulosum microcristallinum, crospovidonum, hypromellosum, lactosum monohydricum 38.7 mg, magnesii stearas, natrii laurilsulfas corresp. natrium 0.01594 mg, Überzug: hydroxypropylcellulosum, hypromellosum, propylenglycolum, e 171, e 172 (flavum), pro compresso obducto. - chronisch-thromboembolische polmonare hypertonie (cteph) und polmonare arterielle hypertonie (pah) - synthetika

Sveits - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - riociguatum - compresse rivestite con film - riociguatum 2 mg, cellulosum microcristallinum, crospovidonum, hypromellosum, lactosum monohydricum 38.20 mg, magnesii stearas, natrii laurilsulfas corresp. natrium 0.01594 mg, Überzug: hydroxypropylcellulosum, hypromellosum, propylenglycolum, e 171, e 172 (flavum), e 172 (rubrum), pro compresso obducto. - chronisch-thromboembolische polmonare hypertonie (cteph) und polmonare arterielle hypertonie (pah) - synthetika

Sveits - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - riociguatum - compresse rivestite con film - riociguatum 2.5 mg, cellulosum microcristallinum, crospovidonum, hypromellosum, lactosum monohydricum 37.70 mg, magnesii stearas, natrii laurilsulfas corresp. natrium 0.01594 mg, Überzug: hydroxypropylcellulosum, hypromellosum, propylenglycolum, e 171, e 172 (flavum), e 172 (rubrum), pro compresso obducto. - chronisch-thromboembolische polmonare hypertonie (cteph) und polmonare arterielle hypertonie (pah) - synthetika

Italia - italiensk - AIFA (Agenzia Italiana del Farmaco)

opella healthcare italy s.r.l. - associazioni di sali ordinarie - associazioni di sali ordinarie

Den europeiske union - italiensk - EMA (European Medicines Agency)

bayer ag - riociguat - ipertensione, polmonare - antipertensivi per l'ipertensione arteriosa polmonare - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. l'efficacia è stata dimostrata in un pah della popolazione eziologie di idiopatica o ereditaria ipa o pah associata a malattia del tessuto connettivo. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.

Den europeiske union - italiensk - EMA (European Medicines Agency)

siga technologies netherlands b.v. - tecovirimat - poxviridae infections; cowpox; monkeypox; vaccinia; smallpox - antivirali per uso sistemico - tecovirimat siga is indicated for the treatment of the following viral infections in adults and children with body weight at least 13 kg:- smallpox- monkeypox- cowpoxtecovirimat siga is also indicated to treat complications due to replication of vaccinia virus following vaccination against smallpox in adults and children with body weight at least 13 kg (see sections 4. 4 e 5. tecovirimat siga should be used in accordance with official recommendations.

Italia - italiensk - AIFA (Agenzia Italiana del Farmaco)

sandoz s.p.a. - nevirapina - nevirapina

Italia - italiensk - AIFA (Agenzia Italiana del Farmaco)

aurobindo pharma (italia) s.r.l. - nevirapina - nevirapina

Italia - italiensk - AIFA (Agenzia Italiana del Farmaco)

sandoz gmbh - nevirapina - nevirapina

Italia - italiensk - AIFA (Agenzia Italiana del Farmaco)

zentiva italia s.r.l. - nevirapina - nevirapina